Proteomic Biomarker Discovery: Review of the Science and Its Challenges with Clinical Samples

References (121)

1. 1 Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [DOI]
2. 2 High density synthetic oligonucleotide arrays [DOI]
3. 3 Gene-Expression Profiles in Hereditary Breast Cancer [DOI]
4. 4 Catalyzed reporter deposition, a novel method of signal amplification application to immunoassays [DOI]
5. 5 Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array [DOI]
6. 6 Cross-Contamination of Cells in Culture [DOI]
7. 7 An investigation into the human serum “interactome” [DOI]
8. 8 Henrietta Lacks, HeLa Cells, and Cell Culture Contamination [DOI]
9. 9 The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays [DOI]
10. 10 Proteome, Phosphoproteome, and N-Glycoproteome Are Quantitatively Preserved in Formalin-Fixed Paraffin-Embedded Tissue and Analyzable by High-Resolution Mass Spectrometry [DOI]
11. 11 The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline [DOI]
12. 12 A Tissue Fixative that Protects Macromolecules (DNA, RNA, and Protein) and Histomorphology in Clinical Samples [DOI]
13. 13 Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies [DOI]
14. 14 Tissue‐based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer [DOI]
15. 15 Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry [DOI]
16. 16 Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs [DOI]
17. 17 The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis [DOI]
18. 18 Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs [DOI]
19. 19 Sample application by in‐gel rehydration improves the resolution of two‐dimensional electrophoresis with immobilized pH gradients in the first dimension [DOI]
20. 20 Mass spectrometry [DOI]
21. 21 Proteomic analysis of the human colon carcinoma cell line (LIM 1215): Development of a membrane protein database [DOI]
22. 22 Identification of 14-3-3σ as a Contributor to Drug Resistance in Human Breast Cancer Cells Using Functional Proteomic Analysis [DOI]
23. 23 Proteome Analysis of Gastric Cancer Metastasis by Two-Dimensional Gel Electrophoresis and Matrix Assisted Laser Desorption/Ionization-Mass Spectrometry for Identification of Metastasis-Related Proteins [DOI]
24. 24 Using Proteomic Approach to Identify Tumor-Associated Antigens as Markers in Hepatocellular Carcinoma [DOI]
25. 25 Identification of pancreatic cancer invasion-related proteins by proteomic analysis [DOI]
26. 26 A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma [DOI]
27. 27 Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens [DOI]
28. 28 Laser Capture Microdissection Applications in Breast Cancer Proteomics [DOI]
29. 29 Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique.A new approach to classification utilizing tumor markers [DOI]
30. 30 Development of Mammalian Serum Albumin Affinity Purification Media by Peptide Phage Display [DOI]
31. 31 Early Detection Cancer Research Network [DOI]
32. 32 Proteomics for the identification of new prostate cancer biomarkers [DOI]
33. 33 Establishment of in-vitro models of chemotherapy resistance [DOI]
34. 34 Urinary proteomics: a tool to discover biomarkers of kidney diseases [DOI]
35. 35 Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival [DOI]
36. 36 Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer.
37. 37 A flexible whole-genome microarray for transcriptomics in three-spine stickleback (Gasterosteus aculeatus) [DOI]
38. 38 Differential protein expression in human corneal endothelial cells cultured from young and older donors.
39. 39 Reflections on applying for NHS ethical approval and governance in a climate of rapid change: prioritising process over principles [DOI]
40. 40 Computer-Aided Evaluation of Breast MRI for the Residual Tumor Extent and Response Monitoring in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy [DOI]
41. 41 Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies [DOI]
42. 42 Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers [DOI]
43. 43 Forward-Phase and Reverse-Phase Protein Microarray [DOI]
44. 44 Modeling stromal-epithelial interactions in disease progression.
45. 45 Expression Profiling of Breast Cancer Cells by Differential Peptide Display [DOI]
46. 46 Moving forward in colorectal cancer research, what proteomics has to tell [DOI]
47. 47 Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy [DOI]
48. 48 Der neue Stellenwert von Tumor- und Gewebebanken im Lichte der Genom- und Proteomforschung [DOI]
49. 49 Alpha feto-protein and albumin in ascitic fluid in hepatocellular carcinoma patients.
50. 50 Biomarker Identification by Feature Wrappers [DOI]
51. 51 Molecular portraits of human breast tumours [DOI]
52. 52 Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring [DOI]
53. 53 Quantitative analysis of complex protein mixtures using isotope-coded affinity tags [DOI]
54. 54 Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents [DOI]
55. 55 Support vector machine classification and validation of cancer tissue samples using microarray expression data [DOI]
56. 56 Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins [DOI]
57. 57 Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement [DOI]
58. 58 Short tandem repeat profiling provides an international reference standard for human cell lines [DOI]
59. 59 The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. [DOI]
60. 60 Quantification of C‐reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C‐labeled peptide standards [DOI]
61. 61 Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment [DOI]
62. 62 High Recovery FASP Applied to the Proteomic Analysis of Microdissected Formalin Fixed Paraffin Embedded Cancer Tissues Retrieves Known Colon Cancer Markers [DOI]
63. 63 Biomarkers: Mining the Biofluid Proteome [DOI]
64. 64 Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research [DOI]
65. 65 Validation of Analytic Methods for Biomarkers Used in Drug Development [DOI]
66. 66 Multiple Reaction Monitoring to Identify Sites of Protein Phosphorylation with High Sensitivity [DOI]
67. 67 Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance [DOI]
68. 68 Reverse-phase protein lysate microarrays for cell signaling analysis [DOI]
69. 69 Proteome Analysis of Microdissected Formalin-fixed and Paraffin-embedded Tissue Specimens [DOI]
70. 70 Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer [DOI]
71. 71 Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer [DOI]
72. 72 Biological differences among MCF-7 human breast cancer cell lines from different laboratories [DOI]
73. 73 Current Practical Applications of Diagnostic Immunohistochemistry in Breast Pathology [DOI]
74. 74 Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance [DOI]
75. 75 Translational Research in Pediatrics: Tissue Sampling and Biobanking [DOI]
76. 76 Biomarker-based dissection of neurodegenerative diseases [DOI]
77. 77 Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67 [DOI]
78. 78 Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy [DOI]
79. 79 Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? [DOI]
80. 80 Screening for Kidney Diseases [DOI]
81. 81 Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets [DOI]
82. 82 Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group [DOI]
83. 83 Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin‐fixed paraffin‐embedded tissues [DOI]
84. 84 Applications of urinary proteomics in biomarker discovery [DOI]
85. 85 Cisplatin resistance induced by decreased apoptotic activity in non‐small‐cell lung cancer cell lines [DOI]
86. 86 Molecular network analysis of human microRNA targetome: from cancers to Alzheimer’s disease [DOI]
87. 87 Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer [DOI]
88. 88 Mass spectrometric proteomics profiles of in vivo tumor secretomes: Capillary ultrafiltration sampling of regressive tumor masses [DOI]
89. 89 Evaluation of Cox's model and logistic regression for matched case‐control data with time‐dependent covariates: a simulation study [DOI]
90. 90 Assessment of early docetaxel response in an experimental model of human breast cancer using DCE‐MRI, ex vivo HR MAS, and in vivo1H MRS [DOI]
91. 91 Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status [DOI]
92. 92 Beyond prostate-specific antigen: alternate serum markers [DOI]
93. 93 Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! [DOI]
94. 94 Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID? [DOI]
95. 95 Preparing multiple-reaction monitoring for quantitative clinical proteomics [DOI]
96. 96 Comparative Analysis of the Protein Profiles from Primary Gastric Tumors and Their Adjacent Regions: MAWBP Could Be a New Protein Candidate Involved in Gastric Cancer [DOI]
97. 97 Dementia screening, biomarkers and protein misfolding [DOI]
98. 98 Proteomic approaches for cancer biomarker discovery in plasma [DOI]
99. 99 Optimization and validation of small quantity RNA profiling for identifying TNF responses in cultured human vascular endothelial cells [DOI]
100. 100 Accurate Identification of HER2-Positive Patients Is Essential for Superior Outcomes With Trastuzumab Therapy [DOI]
101. 101 The Human Plasma Proteome [DOI]
102. 102 Correlation between Protein and mRNA Abundance in Yeast [DOI]
103. 103 Toward a Human Blood Serum Proteome [DOI]
104. 104 Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update [DOI]
105. 105 Comparative Proteomic Phenotyping of Cell Lines and Primary Cells to Assess Preservation of Cell Type-specific Functions [DOI]
106. 106 A Mass Spectrometry-based Proteomic Approach for Identification of Serine/Threonine-phosphorylated Proteins by Enrichment with Phospho-specific Antibodies [DOI]
107. 107 Cancer Biomarkers: Can We Turn Recent Failures into Success? [DOI]
108. 108 Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation [DOI]
109. 109 The cancer secretome: a reservoir of biomarkers [DOI]
110. 110 High-Resolution Two-Dimensional Electrophoresis [DOI]
111. 111 Large-scale protein identification using mass spectrometry [DOI]
112. 112 BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer [DOI]
113. 113 The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics [DOI]
114. 114 Proteomic Characterization of Nipple Aspirate Fluid: Identification of Potential Biomarkers of Breast Cancer [DOI]
115. 115 Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer [DOI]
116. 116 Analysis of molecular profile data using generative and discriminative methods [DOI]
117. 117 Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801) [DOI]
118. 118 Mass spectrometry for protein identification and the study of post translational modifications.
119. 119 Moving forward in colorectal cancer research, what proteomics has to tell
120. 120 Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus [DOI]
121. 121 [Usefulness of PSA test for diagnosis of prostatic cancer].

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Diagnostic Modalities of Tuberculosis- Then and Now — shares topic coverage
• D-Dimer: A Primer Biomarker in COVID-19 — shares topic coverage
• Elevated Peripheral Blood IL-6 Levels: A Novel Biomarker for Assessing Inflammation and Exacerbation Risk in Pediatric Bronchial Asthma — shares topic coverage
• Reproductive & Biomarker Response to a Daily Dose of Instant Noodle Seasoning in Male Albino Rats (Rattus norvegicus) — shares topic coverage
• Impact of Certain Heavy Metals on Histology and Physiology of Fishes: Interpretative Study — shares topic coverage